News
PolyPid to Participate in Upcoming Investor Conferences
PETAH TIKVA, Israel, Feb. 23, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will present at the Raymond...
PolyPid Announces 100th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX for the Prevention of Post-Abdominal Surgery Incisional Infections
Top-line Data Anticipated by Year End 2021 Enrollment Also Continues to Progress in Company's Second Phase 3 Clinical Trial, SHIELD II PETAH TIKVA, Israel, Feb. 16, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve surgical...
PolyPid Ltd. Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
100 Patients Enrolled into Phase 3 SHIELD I and SHIELD II Trials of D-PLEX100 in Abdominal SurgeryRecently Initiated Phase 3 SHIELD II TrialGranted Breakthrough Therapy Designation from FDA for D-PLEX100 for Prevention of SSIs in Patients Undergoing Elective...
PolyPid to Report Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights on February 10, 2021
PETAH TIKVA, Israel, Jan. 27, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it...
PolyPid Announces Positive Preclinical Data from OncoPLEX Intra-Tumoral Cancer Therapy Program
Single Local Treatment of OncoPLEX Showed Improved Overall Survival and Significantly Less Tumor Recurrence, and Reduced Systemic Toxicity Compared to Multiple Injections with Standard Systemic Chemotherapy in a Syngeneic Mouse Model for Solid Tumors of Colon...
PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX for the Prevention of Post-Abdominal Surgery Incisional Infections
Enrollment in SHIELD I, the First Phase 3 Clinical Trial Continues to Progress, with Top-line Data Anticipated in Second Half of 2021 PETAH TIKVA, Israel, Dec. 16, 2020 -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on...
PolyPid to Host Key Opinion Leader Call Discussing D-PLEX and the Prevention of Surgical Site Infections
PETAH TIKVA, Israel, Dec. 03, 2020 -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that...
PolyPid Granted Breakthrough Therapy Designation from FDA for D-PLEX for the Prevention of Surgical Site Infections in Colorectal Surgery
PETAH TIKVA, Israel, Nov. 24, 2020 -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that...
PolyPid Ltd. Provides Corporate Update and Reports Third Quarter 2020 Financial Results
Over 50% of planned 60 centers for ongoing Phase 3 SHIELD I trial of D-PLEX100 in abdominal surgery have received IRB approval Phase 3 SHIELD II trial advanced; preparations underway to initiate by year-end 2020 Conference Call Scheduled for today at 8:30 a.m. ET...
PolyPid to Participate in Three Upcoming Investor Conferences
PETAH TIKVA, Israel, Nov. 04, 2020 -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it...